Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.

ABSTRACT:

Purpose

To determine whether the Royal Marsden Hospital (RMH; London, UK) prognostic score for phase I patients can be validated in a large group of individuals seen in a different center and whether other prognostic variables are also relevant, we present an analysis of 1,181 patients treated in the MD Anderson Cancer Center (MDACC; Houston, TX) phase I clinic.

Experimental design

Medical records of 1,181 consecutive patients who were treated on at least one trial in the phase I clinic were reviewed.

Results

The median age was 58 years and 50% were women. The median number of prior therapies was four and median survival 10 months [95% confidence interval (CI), 9.1-10.9 months]. Independent factors that predicted shorter survival in a multivariate Cox model and could

SUBMITTER: Wheler J 

PROVIDER: S-EPMC4176886 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature